These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16201910)

  • 61. Targeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency.
    Vickers TA; Freier SM; Bui HH; Watt A; Crooke ST
    PLoS One; 2014; 9(10):e110615. PubMed ID: 25334092
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Computational identification of biologically functional non-hairpin GC-helices in human Argonaute mRNA.
    Dornseifer S; Sczakiel G
    BMC Bioinformatics; 2013 Apr; 14():122. PubMed ID: 23574946
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Computational prediction of efficient splice sites for trans-splicing ribozymes.
    Meluzzi D; Olson KE; Dolan GF; Arya G; Müller UF
    RNA; 2012 Mar; 18(3):590-602. PubMed ID: 22274956
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oligomeric nucleic acids as antivirals.
    Mescalchin A; Restle T
    Molecules; 2011 Jan; 16(2):1271-96. PubMed ID: 21278679
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fundamental differences in the equilibrium considerations for siRNA and antisense oligodeoxynucleotide design.
    Lu ZJ; Mathews DH
    Nucleic Acids Res; 2008 Jun; 36(11):3738-45. PubMed ID: 18483081
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of sequence motifs significantly associated with antisense activity.
    McQuisten KA; Peek AS
    BMC Bioinformatics; 2007 Jun; 8():184. PubMed ID: 17555590
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An in vitro selection scheme for oligonucleotide probes to discriminate between closely related DNA sequences.
    Brukner I; El-Ramahi R; Gorska-Flipot I; Krajinovic M; Labuda D
    Nucleic Acids Res; 2007; 35(9):e66. PubMed ID: 17426126
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systematic search for natural antisense transcripts in eukaryotes (review).
    Røsok O; Sioud M
    Int J Mol Med; 2005 Feb; 15(2):197-203. PubMed ID: 15647831
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Conformationally restricted carbohydrate-modified nucleic acids and antisense technology.
    Herdewijn P
    Biochim Biophys Acta; 1999 Dec; 1489(1):167-79. PubMed ID: 10807006
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Concepts to automate the theoretical design of effective antisense oligonucleotides.
    Far RK; Nedbal W; Sczakiel G
    Bioinformatics; 2001 Nov; 17(11):1058-61. PubMed ID: 11724735
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A potent inhibitor of prothrombin gene expression as a result of standardized target site selection and design of antisense oligonucleotides.
    Böhl M; Schwenzer B
    Oligonucleotides; 2005; 15(3):172-82. PubMed ID: 16201905
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.
    Kretschmer-Kazemi Far R; Sczakiel G
    Nucleic Acids Res; 2003 Aug; 31(15):4417-24. PubMed ID: 12888501
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Local RNA target structure influences siRNA efficacy: a systematic global analysis.
    Overhoff M; Alken M; Far RK; Lemaitre M; Lebleu B; Sczakiel G; Robbins I
    J Mol Biol; 2005 May; 348(4):871-81. PubMed ID: 15843019
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability.
    Patzel V; Steidl U; Kronenwett R; Haas R; Sczakiel G
    Nucleic Acids Res; 1999 Nov; 27(22):4328-34. PubMed ID: 10536139
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Technical improvements in the computational target search for antisense oligonucleotides.
    Far RK; Leppert J; Frank K; Sczakiel G
    Oligonucleotides; 2005; 15(3):223-33. PubMed ID: 16201910
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.